Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Phase: Phase 1
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Sharon Walsh, Ph.D., Principal Investigator, Affiliation: Johns Hopkins University
Summary
The purpose of this study is to characterize the effects of enadoline compared to
hydromorphone and butorphanol.
Clinical Details
Official title: Therapeutic Potential of Kappa-Opioids Against Cocaine
Study design: Screening
Eligibility
Minimum age: 21 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
opiate experienced, healthy
Exclusion Criteria:
physical dependence on opioids, barbiturates or alcohol
Locations and Contacts
Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland 21224 6823, United States
Additional Information
Starting date: July 1996
Ending date: December 1998
Last updated: June 23, 2005
|
